Suvorexant shows promise for menopause-related insomnia: study
Clinicians say the orexin receptor antagonist is both well-tolerated and efficacious
Postmenopausal women who experience chronic insomnia may benefit from the dual orexin receptor antagonist suvorexant, a small US study suggests.
Researchers say the drug, which was well-tolerated among participants, could provide a novel therapeutic option for those with vasomotor symptom-associated insomnia.
